{"analyses":[{"ciLowerLimit":"0.14","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.49","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.09","pValueComment":"1-sided p-value","paramType":"Odds Ratio (OR)","paramValue":"0.45","statisticalComment":"Stratified Chi-Square by performance status and histology","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57","upperLimit":"88","value":"74"},{"groupId":"OG001","lowerLimit":"64","upperLimit":"91","value":"80"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1): Complete Response (CR), Disappearance of all measurable and non-measurable disease; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (STA): Does not qualify for CR, PR, Progression or Symptomatic Deterioration. Disease Control Rate (DCR) = CR + PR + STA\n\nAll target measurable lesions must be assessed using the same techniques as baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cediranib maleate alone PO QD in the absence of disease progression or unacceptable toxicity.\n\nCediranib Maleate: Given orally\n\nCisplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPemetrexed Disodium: Given IV","id":"OG000","title":"Phase II Cisplatin-pemetrexed Cediranib 20mg"},{"description":"Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive placebo alone PO QD in the absence of disease progression or unacceptable toxicity.\n\nPlacebo: Given orally\n\nCisplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPemetrexed Disodium: Given IV","id":"OG001","title":"Phase II Cisplatin-pemetrexed Placebo"}],"paramType":"NUMBER","populationDescription":"Eligible patients with baseline eligible disease per RECIST 1.1 were included in the analysis.","reportingStatus":"POSTED","timeFrame":"Disease assessment will be repeated every 6 weeks until disease progression, up to 3 years.Disease control rate is documented for as long as the patient remains on protocol treatment.","title":"Disease Control Rate by RECIST 1.1 (Phase II)","type":"SECONDARY","unitOfMeasure":"percentage of analyzed participants"}